Bear Stearns maintains Amgen at peer perform

Amgen was maintained at peer perform by Bear Stearns analyst Mark Schoenebaum after meeting with company management. Schoenebaum said third-quarter share gains, market growth and pipeline progression support the rating and a third-quarter top-line miss was likely due to minor inventory fluctuations. Shares of the Thousand Oaks, Calif.-based biotechnology were down $1.39, or 1.85%, at $73.90 on volume of 8,656,929 shares versus the three-month running average of 8.418,480 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.